Bulletin
Investor Alert

New York Markets Close in:

Moderna Inc.

NAS: MRNA

GO
/marketstate/country/us

Market open

 --Real time quotes

Dec 1, 2021, 2:12 p.m.

/zigman2/quotes/205619834/composite

$

324.82

Change

-27.61 -7.83%

Volume

Volume 16.13m

Real time quotes

/zigman2/quotes/205619834/composite

Previous close

$ 352.43

$ 324.82

Change

-27.61 -7.83%

Day low

Day high

$312.72

$336.36

Open

52 week low

52 week high

$102.66

$497.49

Open

Company Description

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therap...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Valuation

P/E Ratio (with extraordinary items)

21.66

Price to Sales Ratio

49.59

Price to Book Ratio

16.27

Price to Cash Flow Ratio

19.77

Enterprise Value to EBITDA

-189.27

Enterprise Value to Sales

11.71

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

617,996.00

Income Per Employee

-574,665.00

Receivables Turnover

1.13

Total Asset Turnover

0.18

Liquidity

Current Ratio

1.43

Quick Ratio

1.42

Cash Ratio

1.05

Profitability

Gross Margin

95.12

Operating Margin

-94.99

Pretax Margin

-92.67

Net Margin

-92.99

Return on Assets

-16.74

Return on Equity

-39.99

Return on Total Capital

-37.14

Return on Invested Capital

-36.66

Capital Structure

Total Debt to Total Equity

9.28

Total Debt to Total Capital

8.49

Total Debt to Total Assets

3.24

Long-Term Debt to Equity

8.09

Long-Term Debt to Total Capital

7.41

Officers and Executives

Name Age Officer Since Title
Mr. Stéphane Bancel 47 2011 President, Founding CEO & Director
Dr. Stephen Hoge 43 2013 SVP-Corporate Development & New Drug Concepts
Mr. David W. Meline 62 2020 Chief Financial Officer
Dr. Paul Burton - 2021 Chief Medical Officer
Mr. Juan Andres 54 2017 Chief Technical Operations & Quality Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
11/22/2021 Juan Andres
See remarks
15,000   Disposition at $268.18 per share. 4,022,700
11/22/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
11/22/2021 Juan Andres
See remarks
10,000   Derivative/Non-derivative trans. at $14.22 per share. 142,200
11/19/2021 Juan Andres
See remarks
5,000   Disposition at $265.71 per share. 1,328,550
11/19/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
11/18/2021 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $245.89 per share. 2,458,900
11/17/2021 Stéphane Bancel
Chief Executive Officer; Director
4,000   Gift at $0 per share. 0
11/17/2021 Stéphane Bancel
Chief Executive Officer; Director
9,000   Disposition at $234.57 per share. 2,111,130
11/17/2021 Juan Andres
See remarks
5,000   Disposition at $234.57 per share. 1,172,850
11/17/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
11/15/2021 Stephen Hoge
President
15,000   Disposition at $231.01 per share. 3,465,150
11/15/2021 Juan Andres
See remarks
5,000   Disposition at $231.01 per share. 1,155,050
11/15/2021 Stephen Hoge
President
10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
11/15/2021 Stephen Hoge
President
5,000   Derivative/Non-derivative trans. at $10.9 per share. 54,500
11/15/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
11/12/2021 Stephen Hoge
President
5,000   Disposition at $225.86 per share. 1,129,300
11/12/2021 Juan Andres
See remarks
5,000   Disposition at $225.86 per share. 1,129,300
11/12/2021 Stephen Hoge
President
5,000   Derivative/Non-derivative trans. at $10.9 per share. 54,500
11/12/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
11/11/2021 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $227.67 per share. 2,276,700
11/10/2021 Stéphane Bancel
Chief Executive Officer; Director
30,000   Gift at $0 per share. 0
11/10/2021 Stéphane Bancel
Chief Executive Officer; Director
4,000   Gift at $0 per share. 0
11/10/2021 Stéphane Bancel
Chief Executive Officer; Director
9,000   Disposition at $230 per share. 2,070,000
11/10/2021 Juan Andres
See remarks
5,000   Disposition at $230 per share. 1,150,000
11/10/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
11/08/2021 Juan Andres
See remarks
15,000   Disposition at $233.13 per share. 3,496,950
11/08/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
11/08/2021 Juan Andres
See remarks
10,000   Derivative/Non-derivative trans. at $14.22 per share. 142,200
11/05/2021 Juan Andres
See remarks
5,000   Disposition at $240 per share. 1,200,000
11/05/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
/news/latest/company/us/mrna

MarketWatch News on MRNA

  1. The Dow Bounces Back in Volatile Week

    38 min ago

    - Jacob Sonenshine

  2. Moderna Stock Tanks After Losing Patent Dispute. What Comes Next.

    11:58 a.m. Today

    - Ben Levisohn

  3. Oil prices rise as some traders bet that OPEC will pause its monthly output increases

    11:23 a.m. Today

    - Myra P. Saefong

  4. Moderna Inc. stock underperforms Tuesday when compared to competitors

    4:31 p.m. Nov. 30, 2021

    - MarketWatch Automation

  5. Oil prices suffer steepest monthly decline since March 2020

    3:23 p.m. Nov. 30, 2021

    - Myra P. Saefong

  6. Oil futures suffer largest monthly loss since March 2020

    2:53 p.m. Nov. 30, 2021

    - Myra P. Saefong

  7. Gold settles lower on Powell testimony amid concerns about omicron

    2:40 p.m. Nov. 30, 2021

    - Myra P. Saefong

  8. Gold futures settle lower for the session and month

    1:54 p.m. Nov. 30, 2021

    - Myra P. Saefong

  9. Loading more headlines...
/news/nonmarketwatch/company/us/mrna

Other News on MRNA

  1. Stocks Rebound as Seesaw Moves on Omicron Continue

    39 min ago

    - Joe Wallace

  2. Top ETF Stories of November

    1:00 p.m. Today

    - Zacks.com

  3. Why Arbutus Biopharma Is Rocketing Higher Today

    12:20 p.m. Today

    - Motley Fool

  4. Why Carnival Stock Investors Have No Worries Today

    11:57 a.m. Today

    - Motley Fool

  5. What We Know About the New Variant

    11:30 a.m. Today

    - Gabriele Steinhauser

  6. Moderna loses patent fight against Arbutus related to vaccines; Arbutus up 40%

    10:47 a.m. Today

    - Seeking Alpha

  7. Moderna's (MRNA) Stock Falls on Omicron Variant Concerns

    9:49 a.m. Today

    - Zacks.com

  8. Salesforce, Snowflake, Zscaler, Box: What to Watch in the Stock Market Today

    9:47 a.m. Today

    - James Willhite

  9. Stock Market News for Dec 1, 2021

    9:19 a.m. Today

    - Zacks.com

  10. Greece imposes €100 monthly fines on unvaccinated residents over 60

    6:55 a.m. Today

    - Seeking Alpha

  11. 2 Stocks to Buy If You Are Worried About the New Coronavirus Variant

    6:40 a.m. Today

    - Motley Fool

  12. Will Moderna Become the Next Big Meme Stock?

    6:03 a.m. Today

    - Motley Fool

  13. Is This Latecomer a Better Buy Than Moderna and Pfizer?

    6:00 a.m. Today

    - Motley Fool

  14. South African disease expert says Omicron variant could outweigh Delta - Reuters

    3:15 a.m. Today

    - Seeking Alpha

  15. Powell Vows to Speed-Up Taper, Market Falls

    5:51 p.m. Nov. 30, 2021

    - Zacks.com

  16. Stocks Drop on Omicron Worries, Powell Warning

    5:04 p.m. Nov. 30, 2021

    - Michael Wursthorn

  17. Loading more headlines...

At a Glance

Moderna, Inc.

200 Technology Square

Cambridge, Massachusetts 02139

Phone

1 6177146500

Industry

-

Sector

-

Fiscal Year-end

12/2021

Revenue

$803.40M

Net Income

$-747.06M

2020 Sales Growth

1234.3%

Employees

1,300

/news/pressrelease/company/us/mrna

Press Releases on MRNA

  1. Wednesday's ETF Movers: XSD, QVML

    12:01 p.m. Today

    - MarketNewsVideo.com

  2. Penny Stocks To Watch Today: ABUS, Moderna, A Big Win For Small Caps

    11:23 a.m. Today

    - Penny Stocks

  3. Nasdaq 100 Movers: MRNA, MU

    10:49 a.m. Today

    - MarketNewsVideo.com

  4. S&P 500 Movers: MRNA, RL

    10:49 a.m. Today

    - MarketNewsVideo.com

  5. Nasdaq 100 Movers: MRNA, TSLA

    10:29 a.m. Nov. 30, 2021

    - MarketNewsVideo.com

  6. S&P 500 Movers: MRNA, TSLA

    10:28 a.m. Nov. 30, 2021

    - MarketNewsVideo.com

  7. Regeneron Drug Could be Less Effective vs. Omicron

    10:12 a.m. Nov. 30, 2021

    - Baystreet.ca

  8. Asia Mostly Falls Amid Omicron Concern

    8:27 a.m. Nov. 30, 2021

    - Baystreet.ca

  9. 4 Top Biotech Stocks To Watch Now

    5:07 p.m. Nov. 29, 2021

    - StockMarket.com

  10. Nasdaq 100 Movers: PTON, MRNA

    10:49 a.m. Nov. 29, 2021

    - MarketNewsVideo.com

  11. S&P 500 Movers: MRK, MRNA

    10:39 a.m. Nov. 29, 2021

    - MarketNewsVideo.com

  12. Top Stock Market News For Today November 29, 2021

    7:50 a.m. Nov. 29, 2021

    - StockMarket.com

  13. Which Covid-19 Drug Stocks Will Spike Higher?

    9:12 a.m. Nov. 23, 2021

    - Baystreet.ca

  14. Loading more headlines...
Trending Tickers
  • /zigman2/quotes/207505872/composite DISH+1.05%
  • /zigman2/quotes/204151124/composite CURE-1.23%
  • /zigman2/quotes/214908404/composite GFL+1.15%
  • /zigman2/quotes/204236046/composite DUST+1.32%
  • /zigman2/quotes/200683073/composite FRC+0.90%
X
Powered by StockTwits
Link to MarketWatch's Slice.